Tarsus Pharmaceuticals (TARS) Research & Development (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Research & Development of $22.4 million for Q1 2026, up 55.12% year-over-year from $14.4 million in Q1 2025, and up 23.93% quarter-over-quarter from $18.0 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Research & Development (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $22.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 55.12% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $72.3 million (up 29.67% YoY), while the FY2025 annual figure was $64.3 million, up 20.48% from the prior year.
- Research & Development for Q1 2026 stood at $22.4 million, up from $18.0 million in the prior quarter.
- The five-year high for Research & Development was $22.4 million in Q1 2026, with the low at $500000.0 in Q4 2022.
- The 5-year median for Research & Development is $12.4 million (2023), against an average of $13.1 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development slumped 93.78% in 2022, then surged 2561.0% in 2023.
- Tarsus Pharmaceuticals' Research & Development stood at $500000.0 in 2022, then soared by 2561.0% to $13.3 million in 2023, then advanced by 26.82% to $16.9 million in 2024, then advanced by 6.89% to $18.0 million in 2025, then gained by 23.93% to $22.4 million in 2026.
- Business Quant data shows TARS's Research & Development at $22.4 million in Q1 2026, $18.0 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 31.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.01 Mn |
| Mar 31, 2026 | 22.35 Mn |
| Dec 31, 2025 | 18.04 Mn |
| Sep 30, 2025 | 16.28 Mn |
| Jun 30, 2025 | 15.59 Mn |
| Mar 31, 2025 | 14.41 Mn |
| Dec 31, 2024 | 16.87 Mn |
| Sep 30, 2024 | 12.13 Mn |
| Jun 30, 2024 | 12.32 Mn |
| Mar 31, 2024 | 12.07 Mn |
| Dec 31, 2023 | 13.31 Mn |
| Sep 30, 2023 | 12.11 Mn |
| Jun 30, 2023 | 12.55 Mn |
| Mar 31, 2023 | 12.36 Mn |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 10.91 Mn |
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 12.08 Mn |
| Dec 31, 2021 | 8.04 Mn |
| Sep 30, 2021 | 10.21 Mn |